Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: SVY

Global ~$71.2 billion Biobanking Markets, 2020-2026: Collaborations a Critical Requirement for Biobanks to Retain Market Share


DUBLIN, Oct. 1, 2020 /PRNewswire/ -- The "Strategic Commercial Partnerships Transforming the Global Biobanking Market, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The biobanking market is expected to reach a size of ~$71.2 billion by 2026, registering a compound annual growth rate (CAGR) of ~5.2% from 2020.

The biobanking ecosystem is witnessing significant transformation. Emergence of one-stop shops and virtual biobanks, rise in services offered to sustain and improve positioning, and precision medicine are characterizing this transformative environment.
While Europe is the highest contributor to the total market, Asia-Pacific (APAC) is expected to witness the highest growth during the forecast period (2020 to 2026) of this research.

This market will be driven further by innovation in targeted therapeutic applications, high sample utilization of tissue/stem cells, and the increasing demand for bio-data for enabling patient stratification. Significant growth opportunities for biobanks are in the areas of companion diagnostics (CDx) co-development, large-scale genome sequencing projects, immuno-oncology clinical development, digital pathology services, and real-world evidence (RWE) studies.

The shifting industry paradigm towards commercial partnerships with pharmaceutical and biotech companies, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs), as well as diagnostics and digital solution providers is expected to further boost market growth. Biobanks are partnering with end-users for customized research-based engagements as niche providers of samples and services and as data owners. However, they need to better understand the changing end-user needs and transition to innovative value-based data pricing and hybrid models for ensuring operational sustainability in the future.

Collaborations with commercial partners by fulfilling key selection criteria and engaging with well-defined models are a critical requirement for biobanks to retain market share. A number of leading biobanks in the United States, the United Kingdom, Sweden, and Denmark have taken major strides in adopting and implementing industry best practices in the last few years.

Key Topics Covered:

1. Strategic Imperatives

2. Growth Opportunity Analysis, Biobanking Market

3. Growth Opportunity Universe, Biobanking Market

4. Next Steps

For more information about this report visit https://www.researchandmarkets.com/r/bukrxv

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 16:10
Prothena Corporation plc , a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2024 and provided...

at 16:10
Myomo, Inc. ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended...

at 16:10
QuidelOrtho Corporation (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first...

at 16:10
Acadia Pharmaceuticals Inc. today announced its financial results for the first quarter ended March 31, 2024. "In the first quarter of 2024, Acadia delivered net product sales of $205.8 million, representing 74% revenue growth year over year,...

at 16:10
Zai Lab Limited today announced financial results for the first quarter of 2024, along with recent product highlights and corporate updates. "Our first quarter results demonstrate strong commercial execution and pipeline progress across our...

at 16:10
ChromaDex Corp. today announced financial results for the first quarter of 2024. First Quarter 2024 Financial and Recent Operational Highlights Total net sales were $22.2 million, with $17.4 million from Tru Niagen®. Solid gross margin of...



News published on and distributed by: